1Sodoh T, Kangawa K, Minamino N,et al. A new natriuretic peptide in porcine brain. Nature, 1988,332:78-81.
2Ogawa Y, Itoh H, Nakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol, 1995,22:49 - 53.
3Tuinenburg AE, Brundel BJ,et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J cardiovasc Electrophysiol. 1999 Jun;10(6):827 -35.
4Inouc S. Murakami Y, et al. Atrium as a source of BNP in patients with atrial fibrillation. J Card Fail, 2000 Jun;6(2):92 -6.
5Helme Silvet, Yinong Young- Xu. BNP is elevated in outpatients with atrial fibrillation. Am. J Cardiol. 2003 Nov;92(9):c60 -6.
6Ohta Y,Shimada T,et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J cardiol. 2001 Apr; 17 (4) :415 - 20.
7Nakamura M, Kawata Y, Yoshida H, et al. Relationship between plasma atrial and brain natriaretie peptide concentration and hemodynamic parametets during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J. 1992; 124:1283-1288.
8Frustaci A, Chimenti C, et al, Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
9Horie H ,Tsutamoto T, Minai K, et al. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J ,2000,64:965-970.
10Mabuchi N ,Tsutamoto T,et al. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J,2000,64:765-771.
二级参考文献10
1Saoudi N,Schoels W,EL-Sherif N,eds.Atrial flutter and fibrillation:from basic to clinical applications[]..1998
2Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke: the Framingham study[].Stroke.1991
3Caro JJ,Flegel KM,Orejuela ME,et al.Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice[].Canadian Medical Association Journal.1999
4Flegel KM,Shipley MJ,Rise G.Risk of stroke in non-rheumatic atrial fibrillation[].The Lancet.1987
5Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation[].Stroke.2000
6Hart RG,Sherman DG,Easton JD,et al.Prevention of stroke in patients with nonvalvular atrial fibrillation[].Neurology.1998
7Peterson P,Boysen G,Godtfredsen J,et al.Placebo controlled,randomized trial of warfarin and aspirin for prevention of thromboembolic complications on chronic atrial fibrillation: the Compenhagen AFASAK study[].The Lancet.1989
8Feinberg WM,Blackshear JL,Laupacis A,et al.Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications[].Archives of Internal Medicine.1995
9Ezekowitz MD,Bridgers SL,James KE,et al.Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation:Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators[].The New England Journal of Medicine.1992
10Connolly SJ,Laupacis A,Gent M,et al.Canadian atrial fibrillation anticoagulation (CAFA) study[].Journal of the American College of Cardiology.1991
